Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any sex
• People who have been diagnosed with an advanced gastroenteropancreatic neuroendocrine tumour (a type of tumour affecting the digestive system or pancreas), confirmed by tissue testing
• People who have at least one measurable tumour that shows up on a specific type of scan that detects somatostatin receptors (a protein found on certain tumour cells)
• People who have previously been treated with no more than 2 different systemic anti-cancer drug treatments
• People whose blood test results for liver function, blood cell counts, and clotting fall within the ranges required by the trial (the trial site can confirm the specific values)
• People who are generally well enough to carry out light daily activities, with a performance rating of 0 or 1 on the standard medical scale used to measure this
• People who are expected to live for more than 3 months
• People who have read and understood the trial information and are willing to sign a consent form
• People of reproductive potential who agree to use effective contraception during the trial and for at least 3 months after treatment ends, and who are not pregnant or breastfeeding; male participants must also agree to use contraception during and for 3 months after the trial

Who may not be able to join:

• People with severe or uncontrolled diarrhoea causing significant dehydration
• People who have been diagnosed with another cancer in the past 5 years, except for certain skin cancers or early-stage cervical cancer that has been fully treated with surgery
• People who have received certain anti-cancer treatments within a specified period before the trial starts, including targeted drug therapies within 4 weeks, a short-acting hormone-like injection (octreotide) within 1 week, chemotherapy or interferon within 4 weeks, a specific type of liver treatment (chemoembolisation) within 12 months, or any radiation-based peptide therapy at any point in the past
• People who have had other anti-cancer treatments including radiation, liver procedures, or traditional Chinese medicine anti-cancer treatments within 4 weeks before the trial starts
• People who have taken part in another clinical trial within the past 30 days
• People who have had surgery (other than a biopsy) within 28 days before the trial starts, or who have a wound that has not fully healed
• People whose long-term blood sugar control test (HbA1c) result is above 8.5%
• People who have gallstones causing symptoms and have not had surgery to treat them
• People with active cancer that has spread to the brain, or cancer affecting the lining of the brain, that meets certain criteria related to recent scan results or ongoing symptoms (confirm with trial site)
• People whose side effects from previous cancer treatments have not settled down to a mild level, with some exceptions as assessed by the treating doctor
• People with significant uncontrolled conditions affecting the nervous system, digestive system, kidneys, lungs, or other major organs
• People with active hepatitis B with a certain level of virus in the blood, active hepatitis C, HIV, or syphilis
• People with a known allergy to any ingredient in the trial drug or to substances with a similar chemical structure
• People with poorly controlled high blood pressure, significant heart conditions (including certain irregular heartbeats, heart attack history, or heart failure), serious uncontrolled infections, or a recent history of significant bleeding or blood clots
• People with any other condition, test result, or health factor that the trial doctors consider would make participation unsafe or affect the trial results

Important: Always verify eligibility with the trial site directly before applying.